Compare GL & ALGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GL | ALGN |
|---|---|---|
| Founded | 1900 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Industrial Specialties |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.1B | 10.5B |
| IPO Year | 1998 | 2000 |
| Metric | GL | ALGN |
|---|---|---|
| Price | $160.20 | $168.98 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 16 |
| Target Price | $185.18 | ★ $185.79 |
| AVG Volume (30 Days) | 545.1K | ★ 1.1M |
| Earning Date | 10-21-2026 | 10-28-2026 |
| Dividend Yield | ★ 0.82% | N/A |
| EPS Growth | ★ 17.84 | 0.53 |
| EPS | ★ 11.64 | 4.98 |
| Revenue | ★ $5,994,318,000.00 | $387,126,000.00 |
| Revenue This Year | $6.55 | $2.24 |
| Revenue Next Year | $6.20 | $2.86 |
| P/E Ratio | ★ $13.77 | $33.59 |
| Revenue Growth | 3.74 | ★ 23.95 |
| 52 Week Low | $129.21 | $130.23 |
| 52 Week High | $191.55 | $200.44 |
| Indicator | GL | ALGN |
|---|---|---|
| Relative Strength Index (RSI) | 45.24 | 62.33 |
| Support Level | $155.45 | $164.75 |
| Resistance Level | $166.32 | $183.23 |
| Average True Range (ATR) | 3.21 | 6.51 |
| MACD | 0.41 | 1.56 |
| Stochastic Oscillator | 52.19 | 75.56 |
Globe Life Inc is an insurance holding company. It provides a variety of life and supplemental health insurance products and annuities to a broad base of customers. The company's core operations are organized into three reportable segments: life insurance, supplemental health insurance and investments. Investment activities, conducted by the investment segment, focus on seeking investments with a yield and term appropriate to support the insurance product obligations. These investments generally consist of fixed maturities and, over the long term, the expected yields are considered when setting insurance premium rates and product profitability expectations.
Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.